Even if the vaccines prove successful, they face an uncertain future as farmers and feedlot owners worry about who will pick up the extra cost.
Jason Timmerman coaxed a balky calf into a chute on his feedlot one recent afternoon and jabbed a needle into its neck. He was injecting the animal with a new vaccine to make it immune to a dangerous form of the E. coli bacteria.
The calf and thousands of others are part of a large-scale test to see whether animal vaccines are an answer to one of the nation’s most persistent food-safety problems.
The test has been a long time coming. Bureaucratic delays in Washington stalled the arrival of the vaccines for years, even as people continued to become sick and die from eating tainted beef. And now, even if the vaccines prove successful in the ambitious tests that are just getting under way, they face an uncertain future as farmers and feedlot owners worry about who will pick up the extra cost.
“I hope it works,” Timmerman said. “It probably won’t be so good for my pocketbook directly, but it’ll probably be good for the industry.”
Scientists are fairly sure that vaccines like the one Timmerman gave his cattle will not, on their own, wipe out the dangerous strain of E. coli known as O157:H7. But if they prove effective, they could significantly reduce the amount of harmful bacteria that cattle carry into slaughterhouses, which means that safeguards already in place there would have a greater chance of eliminating the remaining germs from the beef supply.
While studies have shown varying degrees of effectiveness, many researchers believe E. coli vaccines can reduce the number of animals carrying the bacteria by 65 to 75 per cent. That may be enough to prevent the surge of E. coli that typically occurs each summer, when the germ thrives and reports of illness increase.
The vaccines may also reduce the number of so-called supershedders, cattle that carry unusually high levels of E. coli, with the potential to overwhelm slaughterhouse safeguards.
“Anything we can do to reduce that inbound load will help us be more successful,” said Mike Chabot, general manager of a Cargill packing plant in Fort Morgan, Colo.
Food poisoning from toxic strains of E. coli, mostly the O157:H7 variety, has become a recurring problem. The strain is responsible for an estimated 73,000 illnesses and 61 deaths across the country each year. Since January 2007, the industry has initiated 52 recalls of beef tainted with E. coli, compared with 20 in the three previous years. In one of the most recent cases, in October, a company in upstate New York recalled more than 500,000 pounds of ground beef after two people died and more than two dozen were sickened.
In an effort to counter the threat, two vaccines have been developed commercially. One, made by a Minnesota company called Epitopix, received preliminary approval from the Agriculture Department in March, meaning it can be sold while research continues. Dr. James D. Sandstrom, general manager of Epitopix, said that about 300,000 head of cattle will get the vaccine in the coming months as part of a series of large trials.
A second vaccine has been developed by Bioniche Life Sciences, a Canadian company. It was approved for use in Canada last year and is awaiting approval in the United States.
Both vaccines spent years tangled in Washington red tape, largely because they straddle the border between animal medicine and human health.
Many E. coli strains live in a cow’s digestive tract without making it sick. But several strains, notably O157:H7, can sicken people who eat it in ground beef or other foods.
Companies have been working on vaccines for close to a decade. The Agriculture Department received its first application for an O157:H7 vaccine in 2001. But by September 2003, the agency determined that it did not have jurisdiction. The agency said it had authority to approve vaccines only for animal health, and E. coli did not make cattle sick.
The Food and Drug Administration determined that it did not have jurisdiction, either. While it regulated many animal medicines as well as drugs aimed at human health, it was not responsible under federal law for animal vaccines.
“It was in both agencies’ netherworld, where neither agency felt they were authorised by law to approve that product,” said Chuck Lambert, a former deputy under secretary for marketing and regulatory programs at the Agriculture Department.
Finally, in March 2005, the Agriculture Department reversed course and said it would take applications. But even as it agreed to review the vaccines, the agency set a high bar for approval.
Officials determined that the vaccines must show at least a 90 per cent reduction in the number of cattle carrying the bacteria. And among cattle that still harboured E. coli after being vaccinated, the agency insisted on a 99.9 per cent reduction in the number of bacteria shed by the animals.
That was more than the vaccines could achieve — and more than the agency demanded of many other vaccines.
Today another roadblock stands in the way of the E. coli vaccines: who will pay for them.
Epitopix said it had not yet set a price for its vaccine. In Canada, Bioniche charges about $3 a dose. The vaccines require two or three doses to be effective, meaning the cost could approach $10 an animal.
Farmers and feedlot owners fear that they will be stuck with the vaccine cost and that it will cut into already tight margins. Timmerman, the feedlot owner, said that in a good year his profit is $25 to $35 an animal.
“The incentive for the vaccine is it’s going to benefit the packer who is vulnerable to recalls and lawsuits,” said Ronald F. Eustis, executive director of the Minnesota Beef Promotion and Research Council, a trade group that represents farmers and feedlot owners. “Unless the farmer, the producers, the rancher is somehow compensated, he’s going to be reluctant to lay out the cash.”
The large-scale study that includes Timmerman’s calves is being coordinated and paid for by Cargill, the food giant that is the biggest producer of ground beef in the country.
It will include close to 100,000 cattle, with the animals going next summer at Cargill’s Fort Morgan slaughterhouse. Tests will be done on the meat, in particular the smaller pieces, known as trim, that go into ground beef. Researchers will look to see if it contains less E. coli than trim from unvaccinated cattle.
E. coli contamination generally starts when bacteria in feces on a cow’s hide are transferred to the carcass. Cargill has added many steps to keep carcasses clean, including steam pasteurisation and hot water washes. But regular tests at the plant still turn up occasional traces of E. coli in trim, underscoring the need for additional steps, like a vaccine.
“It’s definitely a piece of the solution,” said James L. Marsden, a professor of food safety at Kansas State University. “When you combine it with other pieces you may be looking at a real solution, a total solution.” — © 2009 The New York Times News Service